

Xiaowei Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9181042/publications.pdf>

Version: 2024-02-01

18
papers

495
citations

623734

14
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

680
citing authors

#	ARTICLE	IF	CITATIONS
1	DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 2887-2903.	0.9	12
2	OTUD1 Activates Caspase-Independent and Caspase-Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation. <i>Advanced Science</i> , 2021, 8, 2002874.	11.2	37
3	The deubiquitinase USP11 promotes ovarian cancer chemoresistance by stabilizing BIP. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 264.	17.1	13
4	USP12 promotes breast cancer angiogenesis by maintaining midkine stability. <i>Cell Death and Disease</i> , 2021, 12, 1074.	6.3	12
5	JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. <i>Cell Death and Differentiation</i> , 2020, 27, 55-70.	11.2	53
6	TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. <i>Cell Reports</i> , 2020, 30, 98-111.e5.	6.4	35
7	ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness. <i>Cell Death and Differentiation</i> , 2020, 27, 1981-1997.	11.2	30
8	Remodeling of the ARID1A tumor suppressor. <i>Cancer Letters</i> , 2020, 491, 1-10.	7.2	8
9	Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. <i>Cell Death and Disease</i> , 2020, 11, 556.	6.3	44
10	ARID1A Hypermethylation Disrupts Transcriptional Homeostasis to Promote Squamous Cell Carcinoma Progression. <i>Cancer Research</i> , 2020, 80, 406-417.	0.9	22
11	MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2961-2966.	7.1	58
12	ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. <i>Cancer Letters</i> , 2018, 427, 9-17.	7.2	35
13	Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8751-8759.	2.0	17
14	The effects of different vascular carrier patterns on the angiogenesis and osteogenesis of BMSC-TCP-based tissue-engineered bone in beagle dogs. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 542-552.	2.7	27
15	Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. <i>Cancer Letters</i> , 2017, 411, 65-73.	7.2	17
16	The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation. <i>Cancer Letters</i> , 2017, 404, 44-52.	7.2	17
17	S100A7 promotes the migration, invasion and metastasis of human cervical cancer cells through epithelial-mesenchymal transition. <i>Oncotarget</i> , 2017, 8, 24964-24977.	1.8	41
18	MicroRNA-17/20a impedes migration and invasion via TGF- β 2/ITGB6 pathway in esophageal squamous cell carcinoma. <i>American Journal of Cancer Research</i> , 2016, 6, 1549-62.	1.4	15